PETX - The Pharma Scoop: Vanda Meets Endpoints Aratana To Be Acquired Einhorn Invests In NeuBase
Welcome to another edition of the Pharma Scoop, a regular piece featuring offbeat news from undercovered stocks. This is brought to you by Avisol Capital Partners; we run the Total Pharma Tracker ("TPT") MarketPlace service here on Seeking Alpha.
Vanda Pharmaceuticals (VNDA) announced results from a proof-of-concept study called "Motion Sifnos" for treating motion sickness with tradipitant. In the randomized, double blind, Phase 2 study held in the Pacific Ocean, with 126 participants having prior history of motion sickness, a significantly higher percentage of participants experienced vomiting in the placebo arm as compared